Anti-MYO9A monoclonal antibody

Pre-made anti-MYO9A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to MYO9A/MYO9A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2618-Ab-1/ GM-Tg-hg-IP2618-Ab-2Anti-Human MYO9A monoclonal antibodyHuman
GM-Tg-rg-IP2618-Ab-1/ GM-Tg-rg-IP2618-Ab-2Anti-Rat MYO9A monoclonal antibodyRat
GM-Tg-mg-IP2618-Ab-1/ GM-Tg-mg-IP2618-Ab-2Anti-Mouse MYO9A monoclonal antibodyMouse
GM-Tg-cynog-IP2618-Ab-1/ GM-Tg-cynog-IP2618-Ab-2Anti-Cynomolgus/ Rhesus macaque MYO9A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2618-Ab-1/ GM-Tg-felg-IP2618-Ab-2Anti-Feline MYO9A monoclonal antibodyFeline
GM-Tg-cang-IP2618-Ab-1/ GM-Tg-cang-IP2618-Ab-2Anti-Canine MYO9A monoclonal antibodyCanine
GM-Tg-bovg-IP2618-Ab-1/ GM-Tg-bovg-IP2618-Ab-2Anti-Bovine MYO9A monoclonal antibodyBovine
GM-Tg-equg-IP2618-Ab-1/ GM-Tg-equg-IP2618-Ab-2Anti-Equine MYO9A monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2618-Ab-1/ GM-Tg-hg-IP2618-Ab-2; GM-Tg-rg-IP2618-Ab-1/ GM-Tg-rg-IP2618-Ab-2;
GM-Tg-mg-IP2618-Ab-1/ GM-Tg-mg-IP2618-Ab-2; GM-Tg-cynog-IP2618-Ab-1/ GM-Tg-cynog-IP2618-Ab-2;
GM-Tg-felg-IP2618-Ab-1/ GM-Tg-felg-IP2618-Ab-2; GM-Tg-cang-IP2618-Ab-1/ GM-Tg-cang-IP2618-Ab-2;
GM-Tg-bovg-IP2618-Ab-1/ GM-Tg-bovg-IP2618-Ab-2; GM-Tg-equg-IP2618-Ab-1/ GM-Tg-equg-IP2618-Ab-2
Products NameAnti-MYO9A monoclonal antibody
Formatmab
Target NameMYO9A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-MYO9A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2618-Ag-1Recombinant multi-species MYO9A protein


    Target information

    Target IDGM-IP2618
    Target NameMYO9A
    Gene ID4649,270163,171296,701520,487630,101093691,515330,100052350
    Gene Symbol and Synonyms4732465J09Rik,C130068I12Rik,C230003M11,CMS24,MYO9A,myosin-IXa,myr 7
    Uniprot AccessionB2RTY4,Q9Z1N3
    Uniprot Entry NameMYO9A_HUMAN,MYO9A_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000066933
    Target ClassificationN/A

    The target: MYO9A, gene name: MYO9A, also named as . This gene encodes a member of the myosin superfamily. The protein represents an unconventional myosin; it should not be confused with the conventional non-muscle myosin-9 (MYH9). Unconventional myosins contain the basic domains of conventional myosins and are further distinguished from class members by their tail domains. They function as actin-based molecular motors. Mutations in this gene have been associated with Bardet-Biedl Syndrome. [provided by RefSeq, Dec 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.